The current invention relates to compositions and methods for treating head lice using compounds extracted from Cannabis sativa. The method can include a formulation including a compound extracted from cannabis and coconut oil.

Provided are methods for improving the efficacy and success of cell-based therapies by administration of stem cells which have been preconditioned with an inhibitor of soluble epoxide hydrolase (sEHI), as well as kits, stents and patches for administering sEHI-preconditioned stem cells, as sole active agent or in combination with an agent that increases the production and or levels of EETs.

Provided are methods for improving the efficacy and success of cell-based therapies by administration of stem cells which have been preconditioned with an inhibitor of soluble epoxide hydrolase (sEHI), as well as kits, stents and patches for administering sEHI-preconditioned stem cells, as sole active agent or in combination with an agent that increases the production and or levels of EETs.

The present invention is directed to compositions comprising microalgae extracts comprising fucoxanthin. Further provided are compositions and methods for reducing lipid accumulation in cells. Also provided are methods for prevention or treatment of metabolic syndrome, including but not limited to a fatty liver disease, or a fatty kidney disease.

The present invention is directed to compositions comprising microalgae extracts comprising fucoxanthin. Further provided are compositions and methods for reducing lipid accumulation in cells. Also provided are methods for prevention or treatment of metabolic syndrome, including but not limited to a fatty liver disease, or a fatty kidney disease.

We describe that carotenoids provide a prebiotic effect and can be used to improve the health of the gut microbiome.

We describe that carotenoids provide a prebiotic effect and can be used to improve the health of the gut microbiome.

Methods for treating diffuse intrinsic pontine glioma (DIPG) comprising administration of a therapeutically effective amount of an alkylating hexitol (such as dianhydrogalacitol, diacetyldianhydrogalacitol, and dibromodulcitol) are disclosed. Such methods may further comprise administration of other anti-cancer agents. In preferred embodiments, the secondary anti-cancer agent is an inhibitor of Wee1 tyrosine kinase (such as adavosertib). Methods of treating malignancies in general comprising administration of a combination of an alkylating hexitol and an inhibitor of Wee1 tyrosine kinase are also disclosed.

Methods for treating diffuse intrinsic pontine glioma (DIPG) comprising administration of a therapeutically effective amount of an alkylating hexitol (such as dianhydrogalacitol, diacetyldianhydrogalacitol, and dibromodulcitol) are disclosed. Such methods may further comprise administration of other anti-cancer agents. In preferred embodiments, the secondary anti-cancer agent is an inhibitor of Wee1 tyrosine kinase (such as adavosertib). Methods of treating malignancies in general comprising administration of a combination of an alkylating hexitol and an inhibitor of Wee1 tyrosine kinase are also disclosed.

Methods of using small molecule inhibitors of fatty acid oxidation (FAO) as antimicrobials against intracellular Mycobacteria are disclosed. FAO inhibitors including etomoxir, trimetazidine, oxfenicine perhexeline and/or can be used alone, or in combination with known as antimycobacterial agents against intracellular Mycobacteria.